Gene · 1871
Papers3,808
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
141 to 160 of 3,808
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Long non-coding RNA and Evolving drug resistance in lung cancer. | Heliyon | 2023 | 38089985 | PubTator, text mining | PubMed |
| New insights into fibrotic signaling in hepatocellular carcinoma. | Front Oncol | 2023 | 38074679 | PubTator, text mining | PubMed |
| Single cell multi-omics reveal intra-cell-line heterogeneity across human cancer cell lines. | Nat Commun | 2023 | 38071219 | PubTator, text mining | PubMed |
| Mutant-Huntingtin Molecular Pathways Elucidate New Targets for Drug Repurposing. | Int J Mol Sci | 2023 | 38069121 | PubTator, text mining | PubMed |
| Comprehensive Profiling and Therapeutic Insights into Differentially Expressed Genes in Hepatocellular Carcinoma. | Cancers (Basel) | 2023 | 38067357 | PubTator, text mining | PubMed |
| Bioinformatics analysis-based screening of circRNA gene with mainstream expression trend in colorectal cancer and construction of a coexpression regulatory network. | PLoS One | 2023 | 38064496 | PubTator, text mining | PubMed |
| [Research Progress of LncRNA SNHGs in Regulating the Biological Behavior of Non-small Cell Lung Cancer]. | Zhongguo Fei Ai Za Zhi | 2023 | 38061887 | PubTator, text mining | PubMed |
| Regulation and therapeutic potentials of microRNAs to non-small cell lung cancer. | Heliyon | 2023 | 38058618 | PubTator, text mining | PubMed |
| Circular RNA circATP9A promotes non-small cell lung cancer progression by interacting with HuR and by promoting extracellular vesicles-mediated macrophage M2 polarization. | J Exp Clin Cancer Res | 2023 | 38049814 | PubTator, text mining | PubMed |
| SPINK1-induced tumor plasticity provides a therapeutic window for chemotherapy in hepatocellular carcinoma. | Nat Commun | 2023 | 38030644 | PubTator, text mining | PubMed |
| TGFβ-induced circLTBP2 predicts a poor prognosis in intrahepatic cholangiocarcinoma and mediates gemcitabine resistance by sponging miR-338-3p. | JHEP Rep | 2023 | 38023605 | PubTator, text mining | PubMed |
| Comprehensive genomic profiling reveals prognostic signatures and insights into the molecular landscape of colorectal cancer. | Front Oncol | 2023 | 38023196 | PubTator, text mining | PubMed |
| Integrated analysis of single-cell RNA-seq and bulk RNA-seq reveals RNA N6-methyladenosine modification associated with prognosis and drug resistance in acute myeloid leukemia. | Front Immunol | 2023 | 38022588 | PubTator, text mining | PubMed |
| Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A multicenter phase 2 study. | Cell Rep Med | 2023 | 38016482 | PubTator, text mining | PubMed |
| Mechanisms of Regulation of the Expression of miRNAs and lncRNAs by Metformin in Ovarian Cancer. | Pharmaceuticals (Basel) | 2023 | 38004379 | PubTator, text mining | PubMed |
| Ellagic Acid and Cancer Hallmarks: Insights from Experimental Evidence. | Biomolecules | 2023 | 38002335 | PubTator, text mining | PubMed |
| MicroRNAs as Molecular Biomarkers for the Characterization of Basal-like Breast Tumor Subtype. | Biomedicines | 2023 | 38002007 | PubTator, text mining | PubMed |
| Logic-based modeling and drug repurposing for the prediction of novel therapeutic targets and combination regimens against E2F1-driven melanoma progression. | BMC Chem | 2023 | 37993971 | PubTator, text mining | PubMed |
| Multiomics of HER2-low triple-negative breast cancer identifies a receptor tyrosine kinase-relevant subgroup with therapeutic prospects. | JCI Insight | 2023 | 37991016 | PubTator, text mining | PubMed |
| Exosome derived from tumor-associated macrophages: biogenesis, functions, and therapeutic implications in human cancers. | Biomark Res | 2023 | 37981718 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1871/papers?page=8